School of Pharmacy, MMU, Sadopur, Ambala, India.
Amity institute of Pharmacy, Amity University, Noida, India.
Curr Drug Targets. 2019;20(7):756-762. doi: 10.2174/1389450120666181217101812.
An emerging crisis of antibiotic resistance for microbial pathogens is alarming all the nations, posing a global threat to human health. The production of the metalloβ-lactamase enzyme is the most powerful strategy of bacteria to produce resistance. An efficient way to combat this global health threat is the development of broad/non-specific type of metalloβ-lactamase inhibitors, which can inhibit the different isoforms of the enzyme. Till date, there are no clinically active drugs against metallo- β-lactamase. The lack of efficient drug molecules against MBLs carrying bacteria requires continuous research efforts to overcome the problem of multidrug-resistance bacteria. The present review will discuss the clinically potent molecules against different variants of B1 metalloβ-lactamase.
抗生素耐药性的新兴危机正在令所有国家感到震惊，对人类健康构成全球性威胁。金属β-内酰胺酶的产生是细菌产生耐药性的最有力策略。对抗这一全球健康威胁的有效方法是开发广谱/非特异性金属β-内酰胺酶抑制剂，这种抑制剂可以抑制不同同工酶的酶活性。到目前为止，还没有针对金属β-内酰胺酶的临床有效药物。缺乏针对携带金属β-内酰胺酶的细菌的有效药物分子，需要不断努力研究来克服多药耐药菌的问题。本综述将讨论针对不同变异的 B1 金属β-内酰胺酶的临床有效分子。
